Impact of multiple stents implantation in the infarct-related artery on one-year clinical outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention : data from Polish NRDES registry by Dziewierz, Artur et al.
www.kardiologiapolska.pl
Kardiologia Polska 2016; 74, 8: 717–725; DOI: 10.5603/KP.a2016.0020 ISSN 0022–9032
ARTYKUŁ ORYGINALNY / ORIGINAL ARTICLE
The impact of multiple stent implantation  
in the infarct-related artery on one-year clinical  
outcomes of patients with ST-elevation  
myocardial infarction undergoing primary  
percutaneous coronary intervention.  
Data from the Polish NRDES Registry
Artur Dziewierz1, Zbigniew Siudak2, Tomasz Rakowski1, Wojciech Zasada1, Jacek Legutko1,  
Anna Żabówka1, Łukasz Partyka3, Dariusz Dudek2
12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland
3KCRI, Krakow, Poland
A b s t r a c t
Background and aim: We sought to evaluate the impact of multiple stent implantation in the infarct-related artery (IRA) on 
one-year clinical outcomes of patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percu-
taneous coronary intervention (PCI).
Methods and results: Data on 1741 consecutive patients with STEMI, who underwent immediate PCI with implantation 
of ≥ 1 stent, enrolled the National Registry of Drug Eluting Stents (NRDES) were assessed. Patients were stratified based on 
the number of implanted stents in IRA: 1 vs. ≥ 2 stents. At the discretion of operators, ≥ 2 stents in IRA were implanted in 
247 (14.2%) patients. The remaining 1494 patients were treated with a single stent. Patients treated with multiple stents were 
less likely to achieve Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow after primary PCI. Overall mortality at one 
year was 8.3% in the single stent group and 10.3% in the ≥ 2 stents group (p = 0.37; adjusted for propensity score p = 0.13). 
After propensity score matching, patients treated with ≥ 2 stents were at higher risk of definite or probable stent thrombosis 
and urgent revascularisation at one year.
Conclusions: In patients with STEMI undergoing primary PCI, a need for implantation of ≥ 2 stents in IRA carries an increased 
risk of stent thrombosis and urgent revascularisation at one year.
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INTRODUCTION
Coronary stent implantation during primary percutaneous 
coronary intervention (PCI) reduces recurrent ischaemia and 
the risk of target-vessel revascularisation (TVR) as compared 
to balloon angioplasty alone [1]. When anatomically and 
technically feasible, primary PCI with stent implantation is 
the recommended method of reperfusion in patients with 
ST-segment elevation myocardial infarction (STEMI) [2]. 
Introduction of drug-eluting stents (DES) has contributed 
substantially to the reduction of the risk for TVR as compared 
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to the use of bare-metal stents (BMS) [3, 4]. Although even 
using new-generation DES, primary PCI with stent implanta-
tion in patients with acute coronary syndromes (ACS) carries 
an increased risk of stent thrombosis [3–8]. Observed risk of 
stent thrombosis is higher in patients requiring more complex 
revascularisation (longer stents, multiple stents) [6–9]. Confir-
mation of the impact of the number of stents implanted/total 
stent length on clinical outcomes (especially stent thrombosis) 
was drawn from large-scale registries including patients un-
dergoing stent implantation for both ACS and non-ACS [6–8]. 
Previous studies have not addressed this issue specifically 
for patients undergoing primary PCI for STEMI. Also, there 
is a limited amount of data on the impact of the number of 
stents implanted on other clinical outcomes in that group of 
patients. Thus, we sought to evaluate the impact of the im-
plantation of multiple stents in the infarct-related artery (IRA) 
on one-year clinical outcomes of unselected patients with 
STEMI undergoing primary PCI using data from the National 
Registry of Drug Eluting Stents (NRDES) [10–12].
METHODS
Patient population
A detailed description of the NRDES registry design and the 
main results have been previously published [10–12]. Con-
secutive patients with acute myocardial infarction (STEMI or 
non-STEMI), who underwent immediate PCI in 13 high-volume 
interventional cardiology centres in Poland from October 
2010 till October 2011 were enrolled in the registry. For the 
present analysis, data on 1741 (64.8%) registry patients with 
STEMI, who underwent immediate PCI with implantation 
of ≥ 1 stent within native coronary artery lesions or bypass grafts 
were assessed. Patients were stratified based on the number of 
implanted stents in IRA: 1 stent vs. ≥ 2 stents. The treatment 
strategies, including the number and the length of implanted 
stents, were at the discretion of the operator. The NRDES regis-
try complied with the Declaration of Helsinki and was approved 
by the Bioethics Committee at the Jagiellonian University in 
Krakow, Poland (KBET/120/B/2010 on September 30, 2010).
Endpoints
The primary endpoint of this analysis was one-year all-cause 
mortality. Secondary clinical endpoints included: non-fatal 
reinfarction, definite or probable stent thrombosis as defined 
by the Academic Research Consortium [13], urgent revascu-
larisation (PCI and/or coronary artery bypass graft [CABG]), 
and TVR at one-year follow-up. One-year follow-up was 
gathered mainly by telephone. In the case of rehospitalisa-
tion, patients and/or treating centres were asked to provide 
hospitalisation-related documents.
Statistical analysis
Data were analysed according to the established statistical 
standards. Results are presented as numbers of patients 
(percentages) or mean ± standard deviation as applicable. 
Differences in categorical variables were analysed using 
the c2 test or Fisher exact test, as appropriate. Continuous 
variables were compared using unpaired t-test. All statistical 
analyses were performed using JMP software (version 9.0.0; 
SAS Institute, Cary, NC, USA).
Due to the observational character of the study the 
statistical analysis plan included a step of balancing for co-
variates. Balancing was performed for STEMI patients with 
implantation of 1 stent vs. ≥ 2 stents during index primary PCI. 
A one-to-one matched procedure without replacement was 
performed. We modelled the log odds of probability of im-
plantation of ≥ 2 stents as a function of selected confounders 
depending on the subpopulation. Each patient with ≥ 2 stents 
implanted was matched with patient with 1 stent implanted, 
with propensity score matching within a given threshold. If 
more than one subject with 1 stent implanted was found then 
the procedure picked one of these at random. If no subjects 
with 1 stent implanted were found, a subject with ≥ 2 stents 
implanted was dropped from further analysis as a mismatch. 
The confounders list that was balanced consisted of: age, 
gender, previous myocardial infarction, arterial hypertension, 
hyperlipidaemia, diabetes mellitus, chronic kidney disease, 
previous stroke, previous PCI, previous CABG, Killip class on 
admission, arterial access site, number of coronary arteries 
with significant narrowing, IRA — left main coronary artery 
(LMCA), left anterior descending artery (LAD), diagonal branch 
(Dg), intermediate branch (IM), circumflex artery (Cx), mar-
ginal branch (Mg), right coronary artery (RCA), saphenous vein 
graft (SvG), arterial graft; Thrombolysis In Myocardial Infarc-
tion (TIMI) flow before PCI, glycoprotein IIb/IIIa inhibitors dur-
ing PCI, TIMI thrombus grade [14], thrombectomy, and stent 
type. We modified experimentally the propensity similarity 
threshold and confounders list, which were included in the 
propensity score matching to obtain satisfactory balancing, 
i.e. standardised differences for all variables were estimated 
at below 10%. Matched pairs were analysed by paired t-tests 
to assess whether differences in occurrence rates of overall 
death in one-year follow-up between subjects with 1 stent 
vs. ≥ 2 stents implanted were statistically significant or not. 
Estimated risk differences and 95% confidence intervals for 
these differences were calculated. Additionally, to confirm 
that effect of the number of implanted stents in IRA was in-
dependent of the total stent length, logistic regression analysis 
was conducted. Results were then corrected for IRA (LMCA or 
LAD or Dg vs. other), TIMI before PCI (≤ 1 vs. other), and stent 
type (DES vs. BMS) — Model 1, and the same factors plus age, 
gender, access site (femoral vs. other), presence of diabetes 
mellitus, previous stroke, previous myocardial infarction, pre-
vious PCI, previous CABG, Killip class on admission ≤ 2, and 
chronic kidney disease — Model 2. Groups were compared 
using odds ratio with 95% confidence intervals, indicating 
that the odds of implantation of multiple stents rather than 
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the use of a single stent increases (if > 1) the risk of death at 
one-year follow-up. All presented p values are two-sided and 
are considered as statistically significant if < 0.05.
RESULTS
Baseline characteristics
In the NRDES registry database, we identified 1741 patients 
with STEMI treated with ≥ 1 stent during primary PCI. At the 
discretion of operators, ≥ 2 stents in IRA were implanted in 
247 (14.2%) patients. The remaining 1494 patients were treat-
ed with a single stent (85.8%). As shown in Table 1, patients 
treated with ≥ 2 stents were older, with higher prevalence of 
multi-vessel coronary artery disease, and they presented in 
a higher Killip class on admission to the primary-PCI centre. 
The RCA was identified as IRA more frequently in patients 
with ≥ 2 stents implanted as compared to patients treated 
with a single stent. A trend towards more frequent use of 
aspiration thrombectomy in patients receiving a single stent 
was observed. Despite no difference in TIMI flow at baseline, 
patients treated with multiple stents were less likely to achieve 
complete epicardial flow (TIMI grade 3 flow) after primary 
PCI. The mean total stent length in IRA was 19.6 ± 6.5 mm 
Table 1. Baseline characteristics and invasive treatment details according to number of implanted stents
Variable 1 stent in IRA
(n = 1494)
≥ 2 stents in IRA
(n = 247)
P
Age [years] 63.8 ± 12.2 66.5 ± 11.6 0.0012
Men 1043 (69.8%) 157 (63.6%) 0.05
Previous myocardial infarction 213 (14.3%) 36 (14.6%) 0.92
Arterial hypertension 1026 (68.7%) 175 (70.9%) 0.55
Hyperlipidaemia 847 (56.7%) 150 (60.7%) 0.24
Diabetes mellitus 250 (16.7%) 50 (20.2%) 0.17
Chronic kidney disease 42 (2.8%) 9 (3.6%) 0.42
Previous stroke 53 (3.6%) 12 (4.9%) 0.36
Previous PCI 116 (7.8%) 17 (6.9%) 0.70
Previous CABG 22 (1.5%) 5 (2.0%) 0.57
Killip class on admission: 0.0092
I 1378 (92.2%) 213 (86.2%)
II 44 (3.0%) 11 (4.5%)
III 12 (0.8%) 2 (0.8%)
IV 60 (4.0%) 21 (8.5%)
Access site: 0.14
Femoral 1308 (87.5%) 227 (91.9%)
Radial 185 (12.4%) 20 (8.1%)
Brachial 1 (0.1%) 0 (0%)
Number of coronary arteries with significant narrowing: < 0.0001
1-vessel disease 801 (53.6%) 93 (37.7%)
2-vessel disease 458 (30.7%) 86 (34.8%)
3-vessel disease 211 (14.1%) 61 (24.7%)
LMCA and RCA disease 10 (0.7%) 3 (1.2%)
LMCA disease 14 (0.9%) 4 (1.6%)
Infarct-related artery:
LMCA 32 (2.1%) 7 (2.8%) 0.49
LAD 647 (43.3%) 93 (37.7%) 0.11
Dg 116 (7.8%) 18 (7.3%) 0.90
IM 10 (0.7%) 2 (0.8%) 0.68
Cx 192 (12.9%) 33 (13.4%) 0.84
Mg  75 (5.0%) 13 (5.3%) 0.88
RCA 593 (39.7%) 127 (51.4%) 0.0006
SvG 7 (0.5%) 3 (1.2%) 0.16
Arterial graft 0 (0%) 1 (0.4%) 0.14
Æ
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Outcomes
One-year follow-up data were available for 85% of patients 
(with no difference between study groups). Unadjusted and 
adjusted by propensity score matching primary and secondary 
endpoints are provided in Table 2. A need for implantation 
vs. 40.6 ± 11.8 for the 1 stent vs. ≥ 2 stent group, respec-
tively (p < 0.0001). In the majority of patients unfractionated 
heparin and clopidogrel was used before and during primary 
PCI (bivalirudin in < 2% of patients and prasugrel in < 1% of 
patients with no difference between groups).
Variable 1 stent in IRA
(n = 1494)
≥ 2 stents in IRA
(n = 247)
P
TIMI flow before PCI: 0.26
0 951 (63.7%) 161 (65.2%)
1 144 (9.6%) 31 (12.6%)
2 131 (8.8%) 21 (8.5%)
3 268 (17.9%) 34 (13.8%)
Thrombus grade: 0.43
0–1 670 (44.9%) 122 (49.4%)
2 279 (18.7%) 45 (18.2%)
3 139 (9.3%) 26 (10.5%)
4 135 (9.0%) 16 (6.5%)
5 271 (18.1%) 38 (15.4%)
Glycoprotein IIb/IIIa inhibitors during PCI: 0.60
Abciximab 280 (18.7%) 38 (15.4%)
Tirofiban 1 (0.1%) 0 (0%)
Eptifibatide 92 (6.2%) 17 (6.9%)
None 1121 (75.0%) 192 (77.7%)
Aspiration thrombectomy 498 (33.3%) 66 (26.7%) 0.10
Number of stents in IRA: < 0.0001
1 1494 (100%) 0 (0%)
2 0 (0%) 223 (90.3%)
3 0 (0%) 22 (8.9%)
4 0 (0%) 2 (0.8%)
Stent(s) length in IRA:
> 20 mm 490 (32.8%) 244 (98.8%) < 0.0001
£ 20 mm 1004 (67.2%) 3 (1.2%)
> 25 mm 259 (17.3%) 232 (93.9%) < 0.0001
£ 25 mm 1235 (82.7%) 15 (6.1%)
> 30 mm 88 (5.9%) 198 (80.2%) < 0.0001
£ 30 mm 1405 (94.1%) 49 (19.8%)
Stent type: 0.0009
Drug-eluting stent 448 (33.2%) 53 (22.7%)
Bare-metal stent 998 (66.8%) 191 (77.3%)
TIMI flow after PCI: < 0.0001
≤ 2 63 (4.2%) 29 (11.7%)
3 1431 (95.8%) 218 (88.3%)
Non-IRA PCI 28 (1.9%) 5 (2.0%) 0.80
Values are presented as number of patients (percentage) or mean ± standard deviation; CABG — coronary artery bypass grafting; Cx — left cir-
cumflex coronary artery; Dg — diagonal branch; IM — intermediate branch; IRA — infarct-related artery; LAD — left anterior descending coronary 
artery; LMCA — left main coronary artery; Mg — marginal branch; PCI — percutaneous coronary intervention; RCA — right coronary artery;  
SvG — saphenous vein graft; TIMI — Thrombolysis In Myocardial Infarction 
Table 1. (cont.) Baseline characteristics and invasive treatment details according to number of implanted stents
www.kardiologiapolska.pl
Multiple stents in STEMI
721
Table 2. Primary and secondary endpoints at one-year follow-up (unadjusted and adjusted by propensity score)
Variable Unadjusted results Adjusted results
1 stent 
in IRA
≥ 2 stents 
in IRA
P 1 stent in 
IRA
≥ 2 stents 
in IRA
Risk difference  
(95% CI)
P Pairs  
no.
Death 8.3% 10.3% 0.37 15.9% 10.2% 5.7% (–1.7%; 13.1%) 0.13 157
Stent thrombosis 0.9% 2.4% 0.22 0% 4.0% –4.0% (–8.0%; –0.1%) 0.0449 99
TVR 1.3% 1.8% 0.63 0% 3.0% –3.0% (–6.5%; 0.4%) 0.08 99
Reinfarction 3.9% 7.3% 0.0411 2.1% 8.3% –6.2% (–12.6%; 0.2%) 0.06 97
Urgent PCI 6.0% 8.4% 0.29 2.0% 8.2% –6.1% (–12.4%; 0.2%) 0.06 98
Urgent CABG 1.3% 2.5% 0.36 1.1% 2.1% –1.1% (–3.1%; 1.0%) 0.32 95
Urgent PCI or CABG 7.2% 22.1% 0.13 2.1% 10.6% –8.5% (–15.0%; –2.0%) 0.0106 94
Values are presented as percentages of patients; CABG — coronary artery bypass grafting; CI — confidence interval; IRA — infarct-related artery; 
PCI — percutaneous coronary intervention; TVR — target-vessel revascularisation 
Table 3. Primary and secondary endpoints at one-year follow-up according to the number of stents and the total stent length 
(unadjusted and adjusted)
Unadjusteda Adjusted (Model 1)b Adjusted (Model 2)c
Odds ratio  
(95% CI)
P Odds ratio  
(95% CI)
P Odds ratio  
(95% CI)
P
Death
Number of stents in IRA (1 vs. ≥ 2) 0.80 (0.38–1.60) 0.53 0.51 (0.23–1.10) 0.10 0.50 (0.21–1.15) 0.11
Stent(s) length in IRA (per 5 mm) 0.90 (0.80–1.01) 0.07 0.84 (0.74–0.95) 0.0044 0.88 (0.77–1.01) 0.06
Stent thrombosis
Number of stents in IRA (1 vs. ≥ 2) 12.62 (1.92–76.19) 0.0094 11.11 (1.59–72.07) 0.0123 11.71 (1.61–85.25) 0.0139
Stent(s) length in IRA (per 5 mm) 1.54 (1.03–2.50) 0.0346 1.53 (1.01–2.53) 0.07 1.57 (1.03–2.65) 0.06
TVR
Number of stents in IRA (1 vs. ≥ 2) 0.69 (0.09–3.93) 0.69 0.55 (0.06–3.35) 0.55 0.61 (0.07–3.97) 0.63
Stent(s) length in IRA (per 5 mm) 0.85 (0.66–1.15) 0.28 0.83 (0.63–1.12) 0.20 0.83 (0.61–1.15) 0.24
Reinfarction
Number of stents in IRA (1 vs. ≥ 2) 8.66 (2.97–24.90) 0.0001 9.73 (3.26–28.61) 0.0001 7.80 (2.53–23.89) 0.0003
Stent(s) length in IRA (per 5 mm) 1.39 (1.11–1.79) 0.0031 1.43 (1.13–1.85) 0.0042 1.36 (1.08–1.76) 0.0138
Urgent PCI
Number of stents in IRA (1 vs. ≥ 2) 3.22 (1.32–7.65) 0.0111 3.18 (1.28–7.64) 0.0106 3.26 (1.29–8.00) 0.0108
Stent(s) length in IRA (per 5 mm) 1.23 (1.04–1.48) 0.0147 1.24 (1.04–1.50) 0.0186 1.23 (1.03–1.48) 0.0242
Urgent CABG
Number of stents in IRA (1 vs. ≥ 2) 0.66 (0.10–3.34) 0.63 0.50 (0.07–2.80) 0.47 0.33 (0.04–2.07) 0.26
Stent(s) length in IRA (per 5 mm) 0.79 (0.63–1.03) 0.08 0.77 (0.60–1.01) 0.0480 0.67 (0.48–0.94) 0.0186
Urgent PCI or CABG
Number of stents in IRA (1 vs. ≥ 2) 2.28 (1.02–4.94) 0.0440 2.14 (0.94–4.73) 0.06 2.13 (0.92–4.79) 0.07
Stent(s) length in IRA (per 5 mm) 1.09 (0.95–1.27) 0.23 1.09 (0.94–1.27) 0.27 1.07 (0.93–1.26) 0.36
aModel 0 — number of stents in IRA (1 vs. ≥ 2), stent(s) length in IRA 
bModel 1 — number of stents in IRA (1 vs. ≥ 2), stent(s) length in IRA, IRA (LMCA or LAD or Dg vs. other), TIMI before PCI ≤ 1, stent type (DES vs. BMS) 
cModel 2 — number of stents in IRA (1 vs. ≥ 2), stent(s) length in IRA, IRA (LMCA or LAD or Dg vs. other), TIMI before PCI ≤ 1, stent type (DES 
vs. BMS), age, gender, access site, diabetes mellitus, previous stroke, previous myocardial infarction, previous PCI, previous CABG, Killip class on 
admission ≤ 2, chronic kidney disease 
BMS — bare-metal stent; CABG — coronary artery bypass grafting; CI — confidence interval; DES — drug-eluting stent; Dg — diagonal branch; 
IRA — infarct-related artery; LAD — left anterior descending coronary artery; LMCA — left main coronary artery; PCI — percutaneous coronary 
intervention; TIMI — Thrombolysis In Myocardial Infarction; TVR — target-vessel revascularisation
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of ≥ 2 stents in IRA was associated with increased risk of stent 
thrombosis and urgent revascularisation (PCI or CABG) during 
one-year follow-up. No difference in all-cause mortality was 
observed between groups (Table 2). Logistic regression analysis 
revealed that association between implantation of ≥ 2 stents 
in IRA and increased risk of stent thrombosis was independent 
of the total stent length and baseline clinical characteristics 
(Table  3). Specific subgroup analyses revealed that there 
was no impact of multiple stents implantation on one-year 
all-cause mortality, except for lower mortality in patients 
with the LAD occlusion/stenosis treated with a single stent 
as compared to a treatment with ≥ 2 stents (Fig. 1). Also, the 
one-year mortality was lower for patients treated with a single 
DES as compared to patients treated with ≥ 2 DES. In contrast, 
no difference was observed between patients treated with 
a single vs. multiple BMS.
DISCUSSION
The main finding of the present study is that, in patients with 
STEMI undergoing primary PCI, a need for implantation 
of ≥ 2 stents in IRA carries an increased risk of stent thrombosis 
and urgent revascularisation at one year. However, it does not 
affect one-year mortality.
One in seven patients in the NRDES registry required 
implantation of ≥ 2 stents in IRA during primary PCI for 
STEMI. The implantation of multiple stents may be prompted 
by excessive target lesion length, incomplete lesion cover-
age, and/or endoluminal injury requiring additional stent 
scaffolding beyond the margins of the initial stent deployed. 
Furthermore, multiple overlapping stents may be required 
to repair coronary dissections [15]. Also, the implantation 
of ≥ 2 stents may be needed for the treatment of multiple 
lesions within IRA. Importantly, in line with previous reports, 
implantation of ≥ 2 stents was associated with increased risk 
of stent thrombosis [6, 8]. A higher number of implanted 
stents/longer total stent length itself poses a risk of thrombotic 
complications after stent implantation. It may be more pro-
nounced in patients with overlap implantation of multiple 
stents, as compared to patients without stents overlap [16]. 
On the other hand, in the registries, a need of implantation 
of ≥ 2 stents may be interpreted as a marker of disease se-
verity and a more complex coronary anatomy. In our study, 
multiple stent implantation was required in older patients 
with multi-vessel disease, as well as haemodynamically 
unstable patients. Importantly, haemodynamic instability 
(cardiogenic shock) itself is associated with increased risk of 
stent thrombosis [6, 8]. However, the difference in the risk 
for stent thrombosis between patients treated with 1 stent 
vs. ≥ 2 stents persisted even after correction for potential 
confounding factors and risk profile.
Figure 1. Subgroup analyses for one-year all-cause mortality according to number of implanted stents. Values are presented  
as unadjusted odds ratios with 95% confidence interval (CI); BMS — bare-metal stent; Cx — left circumflex coronary artery;  
DES — drug-eluting stent; LAD — left anterior descending coronary artery; RCA — right coronary artery; TIMI — Thrombolysis  
In Myocardial Infarction
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Interestingly, a trend towards more frequent use of 
aspiration thrombectomy in patients receiving a single stent 
as compared to patients treated with multiple stents was 
observed. Restoration of the patency of IRA with aspira-
tion catheters allows better visualisation of the distal part of 
the vessel, and selection of more appropriate size/length of 
stent [17]. In addition, thrombectomy reduces the thrombus 
burden. Importantly, thrombus presence, especially large 
thrombus presence influences the risk of stent thrombosis 
in patients with STEMI undergoing DES implantation during 
primary PCI [18]. However, the observed difference in the 
risk of stent thrombosis between patients treated with 1 stent 
vs. ≥ 2 stents was not influenced by the thrombus burden.
In previous studies, the implantation of multiple BMS was 
associated with a higher risk of restenosis and TVR [15, 19]. 
The mechanism by which multiple stents are associated with 
restenosis is unknown; one explanation may be related to 
overlapping of the stents, which may provoke a greater degree 
of neointimal proliferation; alternatively, the increased length 
of the stented segment may also evoke a greater degree of 
proliferation [19]. Due to the potent suppression of neointimal 
hyperplasia afforded by DES, the risk of restenosis after DES 
implantation is less dependent on the number of implanted 
stents/total stent length [15]. However, a need of implantation 
of multiple overlapping DES, even new generation DES, itself 
poses a risk for TVR at long-term follow-up [15, 16, 20]. In the 
NRDES registry only a trend toward an increased risk of TVR in 
patients treated with ≥ 2 stents as compared to patients treated 
with a single stent was observed. However, the overall rate of 
TVR was very low, as the risk of ischaemic TVR in patients after 
STEMI is frequently lower than in patients without infarction 
because the infracted territory may be clinically silent when 
restenosis occurs. The observed difference in the need for 
urgent revascularisation was probably related to the difference 
in the presence of multi-vessel disease between the groups.
Future studies should evaluate the impact of multiple 
stent implantations in patients treated with new stents 
designs (i.e. mesh covered stents, self-expandable stents), 
specifically for lesions with a large thrombus burden [21]. 
Due to growing interest in bioresorbable vascular scaffold 
implantation in patients with ACS, it is also necessary to 
assess the impact of multiple bioresorbable vascular scaf-
folds implantation during primary PCI on long-term clinical 
outcomes of patients with STEMI [22, 23]. In addition, new 
P2Y12 inhibitors (prasugrel, ticagrelor) are more effective in 
preventing stent thrombosis in patients treated with stent 
during primary PCI for STEMI [24]. The need for implanta-
tion of ≥ 2 stents in IRA during primary PCI may identify 
the subgroup of patients with a higher risk of ischaemic 
complications and possibly higher benefit from prolonged 
and more aggressive antiplatelet treatment with prasugrel 
or ticagrelor instead of clopidogrel. However, this appealing 
concept requires confirmation in other studies.
Limitations of the study
Our study has several limitations. The main limitation of the 
study was its non-randomised design and the potential of se-
lection bias. Even using propensity score adjustment, we were 
unable to control all patients, operator and centre-related 
factors influencing the association between the number of 
implanted stents and patients’ outcomes. Unfortunately, 
important data on the indication for implantation of another 
stent (i.e. dissection, not completed lesion coverage, treatment 
of long segments) were not available. Also, data on the spatial 
relationship of multiple stents (overlapping vs. separate stents) 
were not collected. Angiographic data were not validated by 
an independent core lab and were based on operators’ visual 
assessment during PCI. In addition, one-year outcome data 
were available only for 85% of patients enrolled in the NRDES 
registry. The incidence of in-stent restenosis may be overes-
timated due to the lack of routine angiographic follow-up. 
Important data on discharge medications and long-term 
compliance of antiplatelet agents were not available. Thus, 
the study results, especially the sub-group analysis results, 
should be considered exploratory and hypothesis-generating.
CONCLUSIONS
In patients with STEMI undergoing primary PCI, a need for 
implantation of ≥ 2 stents in IRA carries an increased risk of 
stent thrombosis and urgent revascularisation at one year.
Impact on daily practice
The need of implantation of ≥ 2 stents in the IRA during 
primary PCI for acute myocardial infarction may identify the 
subgroup of patients with a higher risk of ischaemic complica-
tions, especially stent thrombosis at long-term follow-up. In 
such a group of patients, we can expect greater benefit from 
prolonged and more aggressive antiplatelet treatment with 
prasugrel or ticagrelor instead of clopidogrel. However, this 
appealing concept requires confirmation in other studies.
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Wpływ implantacji wielu stentów w zakresie 
tętnicy odpowiedzialnej za zawał na jednoroczne 
rokowanie kliniczne pacjentów z zawałem serca 
z uniesieniem odcinka ST poddawanych  
zabiegowi angioplastyki wieńcowej.  
Dane z rejestru NRDES
Artur Dziewierz1, Zbigniew Siudak2, Tomasz Rakowski1, Wojciech Zasada1, Jacek Legutko1,  
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S t r e s z c z e n i e
Wstęp i cel: Celem pracy była ocena wpływu implantacji wielu stentów w zakresie tętnicy odpowiedzialnej za zawał (IRA) 
na rokowanie roczne pacjentów z zawałem serca z uniesieniem odcinka ST (STEMI) poddawanych zabiegowi pierwotnej 
przezskórnej interwencji wieńcowej (PCI).
Metody i wyniki: Oceniono dane dotyczące 1741 kolejnych pacjentów z STEMI poddawanych natychmiastowej PCI 
z implantacją ≥ 1 stentu włączonych do rejestru National Registry of Drug Eluting Stents (NRDES). Biorąc pod uwagę liczbę 
implantowanych stentów w obrębie IRA, chorych podzielono na dwie grupy — 1 vs. ≥ 2 stenty. Na podstawie decyzji opera-
tora ≥ 2 stenty w obrębie IRA implantowano u 247 (14,2%) osób. Pozostałych 1494 pacjentów leczono z użyciem 1 stentu. 
Pacjenci leczeni wieloma stentami rzadziej osiągali przepływ Thrombolysis In Myocardial Infarction (TIMI) 3 po zabiegu PCI. 
Łączna roczna śmiertelność wyniosła 8,3% w grupie z 1 stentem i 10,3% w grupie z ≥ 2 stentami (p = 0,37; skorygowana 
przy użyciu skali skłonności: p = 0,13). Po zastosowaniu dopasowania przy użyciu skali skłonności (propensity score matching) 
pacjenci leczeni ≥ 2 stentami charakteryzowali się wyższym ryzykiem wystąpienia pewnej i prawdopodobnej zakrzepicy 
w stencie i pilnej rewaskularyzacji w okresie roku.
Wnioski: U chorych z STEMI poddawanych PCI konieczność implantacji ≥ 2 stentów w IRA wiąże się ze zwiększonym ryzy-
kiem zakrzepicy w stencie i pilną rewaskularyzacą w okresie roku.
Słowo kluczowe: pierwotna angioplastyka, stenty pokrywane, stenty metalowe, zawał serca
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